Immortal Time and Selection Biases in Study of Direct-Acting Antiviral Treatment and Hepatitis C Outcomes—Reply
JAMA Internal Medicine · 2023
DOI: 10.1001/jamainternmed.2023.0557 ↗Kurz gefasst
Kommentar in der Zeitschrift JAMA Internal Medicine, 2023. Verfasst von Eiichi Ogawa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan.
- Division of Gastroenterology and Hepatology, Cedars Sinai Medical Center, Los Angeles, California.
- Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California.
- Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, California.
Zitieren
APA
Ogawa, E., Yeo, Y. H., & Nguyen, M. H. (2023). Immortal Time and Selection Biases in Study of Direct-Acting Antiviral Treatment and Hepatitis C Outcomes—Reply. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2023.0557
Vancouver
Ogawa E, Yeo YH, Nguyen MH. Immortal Time and Selection Biases in Study of Direct-Acting Antiviral Treatment and Hepatitis C Outcomes—Reply. JAMA Internal Medicine. 2023. doi:10.1001/jamainternmed.2023.0557
BibTeX
@article{Ogawa2023,
author = {Ogawa, Eiichi and Yeo, Yee Hui and Nguyen, Mindie H},
title = {Immortal Time and Selection Biases in Study of Direct-Acting Antiviral Treatment and Hepatitis C Outcomes—Reply},
journal = {JAMA Internal Medicine},
year = {2023},
doi = {10.1001/jamainternmed.2023.0557}
}
EUVIMED